GT Biopharma Inc logo

GT Biopharma Inc

$ 1.60 -0.1 (-5.88%) 10:08 PM EST
P/E:
At Loss
P/B:
3.27
Market Cap:
$ 52.09M
Enterprise V:
$ 34.76M
Volume:
107.23K
Avg Vol (2M):
49.88K
Also Trade In:
Volume:
107.23K
Market Cap $:
52.09M
PE Ratio:
At Loss
Avg Vol (2-Month):
49.88K
Enterprise Value $:
34.76M
PB Ratio:
3.27
GF Score:
Year:
Not Enough Data to Display
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Not Enough Data to Display
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Name Current Vs Industry Vs History
Cash-To-Debt 104.97
Equity-to-Asset 0.76
Debt-to-Equity 0.01
Debt-to-EBITDA -0.01
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 17.4
9-Day RSI 28.1
14-Day RSI 35.26
6-1 Month Momentum % -30.96
12-1 Month Momentum % -53.37

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.15
Quick Ratio 4.15
Cash Ratio 4.14

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -120.8

Financials (Next Earnings Date:2023-03-28 Est.)

GTBP's 30-Y Financials

Guru Trades

See Details
To
Not Enough Data to Display

Insider Trades

See Details
To
Not Enough Data to Display

Gurus Latest Trades with NAS:GTBP

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
Not Enough Data to Display

Performance

Dividend
Log
To
Not Enough Data to Display

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Not Enough Data to Display

Valuation Box

Year:
Not Enough Data to Display

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -1.01
Beta 0.39
Volatility % 68.23
14-Day RSI 35.26
14-Day ATR ($) 0.142062
20-Day SMA ($) 1.955
12-1 Month Momentum % -53.37
52-Week Range ($) 1.46 - 4.3
Shares Outstanding (Mil) 32.56

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

GT Biopharma Inc Filings

Document Form Filing Date
No Filing Data

GT Biopharma Inc Analysis

Share your research

Headlines

See More
No news.